← Back to Directory

Menopausal HRT

Hormone Replacement Therapy, MHT, Menopausal Hormone Therapy

Visual ViewRaw DataInteraction Data

Meta Information

ID:menopausal-hrt
Name:Menopausal HRT
Schema Version:1.5

Title

Menopausal HRT

Alternate Names

  • Hormone Replacement Therapy
  • MHT
  • Menopausal Hormone Therapy

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:
30
High Cost:
250
Cost Type:
monthly
Description:
Varies significantly based on insurance coverage and specific formulations (patch, gel, pill).

Summary

Menopausal Hormone Replacement Therapy (HRT) replenishes declining levels of estrogen and progesterone that occur during the menopausal transition. From a healthspan perspective, this mitigates the systemic consequences of hormone loss, which include accelerated bone density decline (osteoporosis), unfavorable shifts in cardiovascular risk factors, metabolic dysregulation, and potential impacts on cognitive function. By addressing this fundamental endocrine shift, HRT aims to preserve physiological function and reduce the risk of age-related diseases in women.

Purpose

Replaces declining hormones to mitigate menopause-related health risks.

Card Summary

Replaces declining estrogen and progesterone to mitigate menopause-related health risks like osteoporosis, cardiovascular changes, and cognitive decline.

Drug Class

Drugs In Class

  • estradiol
  • progesterone
  • estriol
  • testosterone

Impact

Score:
8.5
Justification:
Addresses a fundamental hormonal shift impacting bone, cardiovascular, and neurological health.

Evidence

Grade:
A
Score:
9
Justification:
Extensive data from large RCTs (e.g., WHI) and long-term observational studies.

Safety

Score:
5.5
Justification:
Requires medical supervision; risks (e.g., clots, cancer) depend on formulation and timing.

Flags

  • Requires a prescription and ongoing monitoring by a qualified physician.
  • Risk profile is highly dependent on timing of initiation (early vs. late menopause).
  • Oral estrogen increases clotting risk; transdermal application is generally preferred for healthspan.
  • Unopposed estrogen (without progesterone) increases uterine cancer risk in women with a uterus.
  • Contraindicated for individuals with a history of certain cancers (e.g., breast, uterine).

Verdict

A foundational intervention for post-menopausal women, with careful medical guidance.

Created

2026-04-23T23:44:40.488795Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:
transdermal_patch
Scope:
  • systemic

Indication

Focus:
healthspan
Description:
Menopausal Hormone Replacement Therapy (HRT) replenishes declining levels of estrogen and progesterone that occur during the menopausal transition. From a healthspan perspective, this mitigates the sy...

Typical Protocol

  • Transdermal estradiol (e.g., 0.025-0.1 mg/day) is often preferred to bypass first-pass liver metabolism.
  • Micronized progesterone (e.g., 100-200 mg) is co-administered to protect the uterine lining.
  • Therapy is typically initiated during perimenopause or early menopause for maximum benefit.